Diagnostyka prenatalna w praktyce. Отсутствует
screening for Down syndrome and trisomy 18 in the first trimester of pregnancy. Prenat. Diagn. 2008; 28: 180–185.
19. Kagan K.O. i wsp. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet. Gynecol. 2008; 31: 493–502.
20. Wald N. i wsp. Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy. Prenat. Diagn. 2006; 26: 539–544.
21. Borowski D. Ocena przydatności badań ultrasonograficznych oraz markerów biochemicznych w diagnostyce zagrożeń pierwszego trymestru ciąży. Clin. Exp. Med. Lett. 2006; 47E: 5–62.
22. Kirkegaard I. i wsp. Improved performance of first-trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks. Prenat. Diagn. 2008; 28: 839–844.
23. Lambert-Messerlian G.M. i wsp. Stability of first- and second-trimester serum markers after storage and shipment. Prenat. Diagn. 2006; 26: 17–21.
24. Tul N., Spencer K., Noble P. i wsp. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and pregnancy associated plasma protein-A at 10–14 weeks of gestation. Prenat. Diagn. 1999; 19: 1035–1042.
25. Spencer K., Ong C., Skentou H. i wsp. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and pregnancy associated plasma protein A at 10–14 weeks of gestation. Prenat. Diagn. 2000; 20: 411–416.
26. Kagan K.O., Wright D., Maiz N. i wsp. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet. Gynecol. 2008; 32: 488–492.
27. Wald N., Rish S., Hackshaw A. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. Prenat. Diagn. 2003; 23: 588–592.
28. Westergaard J.G., Sinosich M.J., Bugge M. i wsp. Pregnancy associated plasma protein A in the prediction of early pregnancy failure. Am. J. Obstet. Gynecol. 1983; 145: 67–69.
29. Smith G.C.S., Stenhouse E.J., Crossley J.A. i wsp. Early pregnancy levels of pregnancy associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia and stillbirth. J. Clin. Endocrinol. Metab. 2002; 87: 1762–1767.
30. Dugoff L., Hobbins J.C., Malone F.D. i wsp. First-trimester maternal serum PAPP-A and free beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population based screening study (The FASTER Trial). Am. J. Obstet. Gynecol. 2004; 191: 1446–1451.
31. Goetzl L., Krantz D., Simpson J.L. i wsp. Pregnancy First-trimester tests for impending fetal death 643 associated plasma protein A, free β-hCG, nuchal translucency and risk of pregnancy loss. Obstet. Gynecol. 2004; 104: 30–36.
32. Ong C.Y., Liao A.W., Spencer K. i wsp. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. Br. J. Obstet. Gynaecol. 2000; 107: 1265–1270.
33. Ricciardulli A., Di Iorio A., Liberati M. i wsp. Association between first trimester maternal serum free hCG and PAPP-A and preterm delivery. Ultrasound Obstet. Gynecol. 2004; 24: 28.
34. Yaron Y., Heifetz S., Ochshorn Y. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat. Diagn. 2002; 22: 778–782.
35. Hoffman J.D. i wsp. Down syndrome serum screening also identifies an increased risk for multicystic dysplastic kidney, two-vessel cord, and hydrocele. Prenat. Diagn. 2008; 28: 1204–1208.
36. Spencer K. First trimester maternal serum screening for Down’s syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays. Ann. Clin. Biochem. 2005; 42: 30–40.
37. Gjerris A.C. i wsp. First trimester screening markers are altered in pregnancies conceived after IVF/ICSI. Ultrasound Obstet. Gynecol. 2008; 32: 245.
38. Spencer K. i wsp. First-trimester ADAM12s as early markers of trisomy 21: a promise still unfulfilled? Prenat. Diagn. 2008; 28: 338–342.
39. Spencer K., Cowans N.J., Stamatopoulou A. Maternal serum ADAM12s in the late first trimester of pregnancies with Trisomy 21. Prenat. Diagn. 2008; 28: 422–424.
40. Spencer K., Cowans N.J., Nicolaides K.H. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat. Diagn. 2008; 28: 7–10.
41. Kasper P., Torben L., Lone K. i wsp. First trimester maternal serum PAPP-A, β-hCG and ADAM12 in prediction of small-for-gestational-age fetuses. Prenat. Diagn. 2008; 28: 1131–1135.
42. Spencer K. i wsp. First trimester intact hCG as an early marker of trisomy 21: a promise unrecognised? Prenat. Diagn. 2008; 28: 1156–1159.
43. Christiansen M., Sorensen T.L., Larsen S.O. i wsp. First-trimester maternal serum progesterone in aneuploid pregnancies. Prenat. Diagn. 2008; 28: 319–322.
44. Johnson J. i wsp. First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. Prenat. Diagn. 2013; 33: 1044–1049.
45. Brock D.J., Sutcliffe R.G. Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet 1972; 2: 197–199.
46. Wald N.J., Cuckle H.S., Boreham J. Alpha-fetoprotein screening for open spina bifida: effect of routine biparietal diameter measurement to estimate gestational age. Rev. Epidemiol. Sante. Publique. 1984; 32: 62–69.
47. Cuckle H.S., Wald N.J., Lindenbaum R.H. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984; 1: 926–929.
48. Cuckle H.S., Wald N.J. Screening for Down’s syndrome using serum alpha fetoprotein. Br. Med. J. 1985 Aug 3; 291: 349.
49. Chard T., Lowings C., Kitau M.J. Alpha-fetoprotein and chorionic gonadotropin levels in relation to Down’s syndrome. Lancet 1984; 29: 750.
50. Bogart M., Pandian M., Jones O.W. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal abnormalities. Prenat. Diagn. 1987; 9: 623–630.
51. Krause T.G., Christens P., Wohlfahrt J. i wsp. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome (1). Obstet. Gynecol. 2001 Feb; 97: 277–282.
52. Wald N. i wsp. Maternal serum screening for Down’s syndrome in early pregnancy. Br. Med. J. 1988; 297: 883–887.
53. Canick J.A., Knight G.J., Palomaki G.E. i wsp. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down’s syndrome. Br. J. Obstet. Gynaecol. 1988; 95: 330–333.
54. Alldred S.K., Deeks J.J., Guo B. i wsp. Second trimester serum tests for Down’s Syndrome screening. Cochrane Database Syst Rev 2012 Jun; 13: 6.
55. Malone F.D., Ball R.H., Nyberg D.A. i wsp. FASTER Research Consortium. First-trimester nasal bone evaluation for aneuploidy in the general population. Obstet. Gynecol. 2004 Dec; 104(6): 1222–1228.
56. Nicolaides K.H. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat. Diagn. 2011; 31: 7–15.
57. Wald N., Cuckle H., Densem J. Maternal serum screening for Down’s syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight. Br. J. Obstet. Gynaecol. 1992 Feb; 99: 144–149.
58. Reynolds T., Penney M. The mathematical basis of multivariate risk screening; with special reference to screening for Down’s syndrome associated pregnancy. Ann. Clin. Biochem. 1989; 27: 452–458.
59. Huderer-Duric K., Skrablin S., Kuvacic I. The triple test in predicting fetal aneuploidy: a compromise between sensitivity